Your browser doesn't support javascript.
loading
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
Marchiò, C; Scaltriti, M; Ladanyi, M; Iafrate, A J; Bibeau, F; Dietel, M; Hechtman, J F; Troiani, T; López-Rios, F; Douillard, J-Y; Andrè, F; Reis-Filho, J S.
Afiliação
  • Marchiò C; Department of Medical Sciences, University of Turin, Turin; Division of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Scaltriti M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York; Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York.
  • Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York.
  • Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Boston; Department of Pathology, Harvard Medical School, Boston, USA.
  • Bibeau F; Department of Pathology, Caen University Hospital, Caen, France.
  • Dietel M; Institute of Pathology, Charité, University Medicine Berlin, Berlin, Germany.
  • Hechtman JF; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York.
  • Troiani T; Medical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • López-Rios F; Pathology & Targeted Therapies Laboratory, HM Sanchinarro University Hospital, Madrid, Spain.
  • Douillard JY; European Society for Medical Oncology, Lugano, Switzerland.
  • Andrè F; Department of Medical Oncology, INSERM Unit 981, Institut Gustave Roussy, Villejuif, France. Electronic address: education@esmo.org.
  • Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York.
Ann Oncol ; 30(9): 1417-1427, 2019 09 01.
Article em En | MEDLINE | ID: mdl-31268127
ABSTRACT

BACKGROUND:

NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most frequent mechanism of oncogenic activation of these receptor tyrosine kinases, and biomarkers for the use of TRK small molecule inhibitors. Given the varying frequency of NTRK1/2/3 fusions, crucial to the administration of NTRK inhibitors is the development of optimal approaches for the detection of human cancers harbouring activating NTRK1/2/3 fusion genes. MATERIALS AND

METHODS:

Experts from several Institutions were recruited by the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) to review the available methods for the detection of NTRK gene fusions, their potential applications, and strategies for the implementation of a rational approach for the detection of NTRK1/2/3 fusion genes in human malignancies. A consensus on the most reasonable strategy to adopt when screening for NTRK fusions in oncologic patients was sought, and further reviewed and approved by the ESMO TR and PM WG and the ESMO leadership.

RESULTS:

The main techniques employed for NTRK fusion gene detection include immunohistochemistry, fluorescence in situ hybridization (FISH), RT-PCR, and both RNA-based and DNA-based next generation sequencing (NGS). Each technique has advantages and limitations, and the choice of assays for screening and final diagnosis should also take into account the resources and clinical context.

CONCLUSION:

In tumours where NTRK fusions are highly recurrent, FISH, RT-PCR or RNA-based sequencing panels can be used as confirmatory techniques, whereas in the scenario of testing an unselected population where NTRK1/2/3 fusions are uncommon, either front-line sequencing (preferentially RNA-sequencing) or screening by immunohistochemistry followed by sequencing of positive cases should be pursued.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicoproteínas de Membrana / Proteínas de Fusão Oncogênica / Receptor trkA / Receptor trkB / Receptor trkC / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicoproteínas de Membrana / Proteínas de Fusão Oncogênica / Receptor trkA / Receptor trkB / Receptor trkC / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Itália